This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade (1, 2).  The protocol utilizes a fluorescent method to measure Caspase-3/7 activation.  This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).

• NCL_Method_GTA-14.pdf(PDF | 648 KB)

Researchers should cite this work as follows:

• Stephan Stern, Barry Neun (2020). NCL Method GTA-14. (Version 2.0). NCI Hub. doi:10.17917/95VC-ZP26

  BibTex | EndNote

1. caspase
2. Nanoparticles

The publication is part of the series below:

• Untitled Draft 11

  hkjdsa